Patent: 6,548,529
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 6,548,529
Title: | Heterocyclic containing biphenyl aP2 inhibitors and method |
Abstract: | aP2 inhibiting compounds are provided having the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X-Z and ##STR2## are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing such aP2 inhibitor or a combination of such aP2 inhibitor and another antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin. |
Inventor(s): | Robl; Jeffrey A. (Newtown, PA), Sulsky; Richard B. (West Trenton, NJ), Magnin; David R. (Hamilton, NJ) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 09/519,079 |
Patent Claims: | see list of patent claims |
Details for Patent 6,548,529
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Janssen Biotech, Inc. | REOPRO | abciximab | Injection | 103575 | 12/22/1994 | See Plans and Pricing | 2019-04-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |